Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
A legfontosabb adatok
- Ki végzi
- Sunil G. Iyer
- Hol
- Chicago, Miami, New York és Seattle (Egyesült Államok)Mind a 4 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 45 fő, tervezett
- Kezdés
- 2027. márc. 31.
- Várható befejezés
- 2030. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Asciminib
- Inotuzumab ozogamicin
- A regiszteradat frissítve
- 2026. november 13.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 33 feltétel megnézéseKevesebb
Ki vehet részt
- Documented and confirmed CD22+ R/R Ph+ B-ALL according to the World Health Organization (WHO) classification; Relapsed ALL is defined as the detection of ≥ 5% blasts in the bone marrow with or without non-central nervous system (CNS) extramedullary disease; Refractory ALL is defined as the failure to obtain a CRc after at least two courses of intensive induction or immunotherapy such as blinatumomab, or to CAR-T cells. Persistent MRD without ≥ 5% blasts in the bone marrow will not be sufficient for inclusion
- Disease must be positive for Ph (p190 or p210 transcript) by cytogenetics or PCR
- Disease must be positive for CD22, defined as any percentage of leukemic blasts expressing CD22
- Disease must be positive for t(9;22) by Cytogenetics and FISH. Subjects with complex translocations resulting in BCR::ABL1 fusion protein are eligible
- BCR-ABL mutational panel performed within 90 days prior to start of treatment, including the following 4 mutations: T315I and M244V, A337V, or F359C/I/V mutations. Specific panel may be determined per institution, however must include all aforementioned mutations. Note: T315I mutated patients are only eligible once Dose Level 3 is open to enrollment
- Subject must have recovered (no worse than Grade 1 severity) from effects of all previous treatments
- Able to provide informed consent
- Age ≥18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2 or Karnofsky ≥60%
- Adequate organ function defined by the following parameters:; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x the upper limit of normal (ULN); Total bilirubin ≤1.5x the ULN unless due to known Gilbert's disease or hemolysis due to blood transfusion; For patients with Gilbert's disease: total bilirubin ≤ 3x the ULN; Calculated glomerular filtration rate (GFR) of ≥ 15 mL/min/1.73 m2
- Female patients of childbearing potential must not be nursing or planning to become pregnant
- Female patients of childbearing potential require a negative urine or serum pregnancy test within 30 days of study therapy
- Female patients of childbearing potential must be willing to use at least 1 method of highly effective contraception during the study until 8 months after last dose of inotuzumab ozogamicin, or 1 week after the last dose of asciminib, whichever is later
- Male patients who are sexually active must be willing to use condoms and refrain from sperm donation during the study until 5 months after last dose of inotuzumab ozogamicin
- Willing to provide pretreatment bone marrow aspirate and biopsies samples as well as subsequent bone marrow aspirate and biopsies samples during the study
Ki nem vehet részt
- Presence of severe and/or uncontrollable concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection)
- All prior Philadelphia chromosome-directed TKI therapy must be discontinued at least five days prior to study entry; corticosteroids and hydroxyurea are permitted during this period
- Treatment with chemotherapy, radiotherapy, or biologic therapy within 3 weeks prior to treatment Note: Hydroxyurea or corticosteroids is permitted; Previous treatment with ≥1 BCR-ABL-directed TKI
- Prior allogeneic stem cell transplant < 90 days prior to anticipated treatment start
- Patients with active GVHD (graft versus host disease) and/or receiving immunosuppressive drugs for GVHD
- Patients receiving calcineurin inhibitors < 4 weeks prior to anticipated treatment start
- Prior exposure to INO
- Prior exposure to asciminib
- Clinical suspicion for active CNS involvement by ALL; previously treated CNS involvement is allowed
- Second malignancy requiring treatment within 6 months of study enrollment, with the exception of non-melanoma skin cancers or cancers requiring hormonal therapy only
- Active, uncontrolled infection
- Human immunodeficiency virus (HIV) not controlled by standard therapy
- Active hepatitis B or C infection. Participants whose infections are controlled with antiviral therapy are allowed
- Patients with end stage renal disease requiring dialysis
- Ph-directed TKI within 5 days of treatment start
- The presence of mixed phenotype acute leukemia or CML in lymphoid blast phase
- Presence of BCR-ABL1 M244V, A337V, or F359C/I/V mutations other n-lobe known to confer clinical resistance to asciminib as detected by ABL1 kinase mutational panel
- Patients with T315I mutation as detected by ABL1 kinase mutational panel are excluded from asciminib dose levels lower than 200mg BID
Helyszínek itt: Egyesült Államok
- University of Chicago Comprehensive Cancer CenterChicago, Egyesült ÁllamokContact: Anand Ashwin Patel, MDToborzás még nem indult
- University of Miami - Sylvester Comprehensive Cancer CenterMiami, Egyesült ÁllamokContact: Terrence Bradley, MDToborzás még nem indult
- Columbia University Irving Medical CenterNew York, Egyesült ÁllamokContact: Research Nurse NavigatorRésztvevőt keres
- University of Washington Fred Hutchinson Comprehensive Cancer CenterSeattle, Egyesült ÁllamokContact: Ryan Cassaday, MDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a multi-center phase 1 open-label study to determine the safety of ABL001 and INO in patients with relapsed or refractory Philadelphia chromosome-positive b-cell acute lymphoblastic leukemia.
A vizsgálat csoportja
- Single-ArmA vizsgált kezelés
All participants enrolled to the treatment arm of the study will receive Asciminib in combination with Inotuzumab Ozogamicin. INO is to be dosed in a fractionated schedule as follows: * Prior to achieving compositive complete remission (CRc): 0.8 mg/m2 day 1, 0.5 mg/m2 days 8 and 15 * Once CRc achieved (even if MR3/MR4 not achieved): 0.5 mg/m2 days 1, 8, 15 Asciminib will be administered at a dose of 40, 60, 80, 160, or 200 mg twice daily.
Kezelés: Asciminib és Inotuzumab ozogamicin
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase I Open-label, Multicenter Trial of Asciminib (ABL001) Added to Inotuzumab Ozogamicin (Besponsa®) in Patients With Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia
- A regiszteradat frissítve
- 2026. november 13.